Worldwide Contrast Enhanced Ultrasound Industry to 2028 - Featuring Bracco Diagnostic, General Electric and Siemens Healthcare Among Others - ResearchAndMarkets.com

The "Global Contrast Enhanced Ultrasound Market Size, Share & Trends Analysis Report by Product (Equipment, Contrast Agents), by Type (Non-targeted, Targeted), by End-use (Hospitals, Clinics), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global contrast enhanced ultrasound market size is estimated to reach USD 2.71 billion by 2028, expanding at a CAGR of 4.0%.

Introduction of affordable dyes, increasing sonography procedural volume, and contrast imaging modes becoming an integral feature of ultrasound systems are the prominent factors driving the market.

The increasing prevalence of cardiovascular diseases, liver lesions, renal lesions, gastrointestinal diseases, and vascular diseases globally is anticipated to boost the market growth, as these are major areas of clinical application of Contrast-enhanced Ultrasound (CEUS) systems.

The presence of several potential benefits in CEUS such as being completely radiation-free, quick, cost-efficient, and patient-friendly, in comparison to the contrast-enhanced CT/MRI, is expected to propel the growth of the market.

Increasing approvals of CEUS by regulatory bodies for new indications are expected to propel the growth of the market during the forecast period. For instance, the ultrasound dyes which were originally indicated for cardiac imaging have received an extension of indication for pediatric and liver imaging in several countries.

Contrast Enhanced Ultrasound Market Report Highlights

• Based on product, the equipment segment held the largest revenue share in 2019. This can be attributed to the largest installed base of sonography technology compatible with CEUS
• The contrast agents segment is expected to grow at the fastest rate of 4.0% during the forecast period owing to its approval of usage in the liver and pediatric imaging by the FDA
• Based on type, the non-targeted segment held the largest revenue share in 2019 as most of the commercially available dyes are non-targeted agents
• Numerous clinical trials conducted to determine the potential of diagnostic and therapeutic application of targeted imaging dyes in cancer care are expected to drive the segment during the forecast period
• The hospitals segment held the largest market share in 2019 owing to the increasing number of emergency visits with medical conditions such as abdominal pain, abdominal/thoracic trauma, and cardiac complications
• The clinics segment is anticipated to witness lucrative growth over the forecast period owing to the realization of economic and patient care benefits with the adoption of sonography devices in practice among physicians at primary and secondary care
• In Asia Pacific, the market is expected to grow at the fastest rate owing to the limited accessibility to advanced CT/MRI imaging modalities such as CT and MRI, and the growing burden of cardiovascular disorders in China and India.

Market Dynamics

Drivers

• Increasing prevalence of chronic illness diseases
• Technological advancements
• Extension of indication for use

Restraints

• Low stability of contrast agents
• Procedural complexity
• Availability of alternatives

Companies Mentioned

• Lantheus Medical Imaging Inc.
• Bracco Diagnostic Inc.
• General Electric
• Siemens Healthcare GmbH
• nanoPET Pharma GmbH
• ESAOTE SPA
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/qb49qp

View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005707/en/